Again, real bankers may consider toxic debt if it substantially impacts a raise, meaning that they would have to continue to deal with the toxic debt after the raise. And maybe, if the company had $5M in toxic debt, it would matter, but please, $500-$600K in toxic debt is a check away from $0.00 liabilities. Some here assume that the company and its bankers would have to continue to deal with toxic debt, and then price a deal way below market, well.....thats exactly the implication that some are making anyway. Considering shareholder equity, toxic debt will be the first thing that gets retired, just like the CEO has been saying all along. That hasn't changed.
Again, its what "investors" deem necessary to invest in. Day guys and OTC retailers look only at 2 things, PPS and volume. Thats what they do, and thats all they base investment decisions on. Its nothing more than a stock play to them. They ONLY want to know the company has longevity enough to liquidate their stock, they couldn't care less about the company or its shareholders. We will need to see what the plan going forward looks like, but I have a feeling, again, PPS and volume are the LAST things on their minds, because down here in the OTC cesspool, they don't play, so don't care.
Real investors, the ones that invest and don't sell within 2 years on NASDAQ and NYSE, invest in enterprise value, which considers a lot of actual business metrics, both current, but for large PO type investment, based on future value. Granted, it appears those not invested see this as a big OTC game and are really shooting from the hip based on misinformation or worse. And to them doesn't matter if the stock tanks because they are only invested in online discussions. The nonsense bickering back and forth about toxic debt, whats credible or not, while entertaining, is based solely on speculation, and to some, thats fun, engaging in a battle of wits trying to come up with that nugget to prove, or disprove a future event. What a waste of time.
AI
